Purpose: This retrospective case-series study evaluated efficacy and safety of Endostar combined with chemotherapy in the treatment of advanced bone and soft tissue sarcomas in stage IV.
Materials And Methods: Forty-seven patients diagnosed with stage IV bone and soft tissue sarcomas and treated with chemotherapy in Tianjin Medical University Cancer Institute & Hospital were reviewed. Of these patients, 23 patients were treated with Endostar plus chemotherapy (designated as combined group), and 24 patients received only chemotherapy (designated as control group). Progression-free survival (PFS), overall survival (OS), objective response rate (ORR) and clinical benefit response (CBR) were analyzed to find the difference between these two groups with the purpose to investigate the role of Endostar in metastatic sarcomas.
Results: Endostar combined with chemotherapy had significantly increased PFS. In the combined group and control groups, the median PFS (8.6 months versus 4.4 months) and the CBR (47.8% versus 16.7%) showed significant difference (P = 0.032), while the median overall survival (11.7 months versus 10.6 months, P = 0.658) and the ORR (17.4% versus 8.3%, P = 0.167) showed no significant difference. The common grade 3-4 side effects for both groups were myelosuppression and transient elevation of transaminases.
Conclusion: Endostar combined with chemotherapy had significant activity to increase the PFS and improve CBR in patients with advanced sarcomas, with tolerable side effects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482691 | PMC |
| http://dx.doi.org/10.18632/oncotarget.13545 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: Combination therapy of envafolimab with endostar for advanced non-small cell lung cancer with low PD-L1 expression.
Front Oncol
November 2024
Department of Radiation Oncology, Lianyungang Clinical College of Nanjing Medical University, Lianyungang, China.
In the management of advanced non-squamous non-small cell lung cancer (NSCLC) without driver gene mutations, the current therapeutic strategies encompass chemotherapy, chemotherapy combined with anti-angiogenic therapy, and chemotherapy combined with immunotherapy. For patients with high programmed death-ligand 1(PD-L1) expression, monotherapy with immune checkpoint inhibitors is a viable option. Recognizing that some patients cannot tolerate or decline chemotherapy, clinical practice has introduced non-chemotherapeutic treatment regimens, which have shown promising results.
View Article and Find Full Text PDFClinical efficacy of Endostar continuous infusion combined with concurrent chemoradiotherapy in the treatment of oesophageal squamous cell carcinoma.
Front Med (Lausanne)
October 2024
Department of Radiotherapy, The Affiliated Chuzhou Hospital of Anhui Medical University, Chuzhou, China.
Objective: To evaluate the effectiveness and safety of concurrent chemoradiotherapy using Endostar continuous infusion for treating oesophageal squamous cell carcinoma (OSCC).
Method: A total of 62 patients with oesophageal carcinoma were divided into three groups: the Endostar continuous infusion group ( = 27), the Endostar intravenous drip group ( = 21) and the concurrent chemoradiotherapy group ( = 14). All patients underwent oesophageal radiotherapy (56-60 Gy) alongside concurrent chemotherapy (4 mg of raltitrexed +100 mg of oxaliplatin, two cycles).
β-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer.
BMC Immunol
September 2024
Changzhou Medical Center, Nanjing Medical University, Changzhou, 213003, China.
Article Synopsis
- Immune checkpoint inhibitor rechallenge using β-glucan, Envafolimab, and Endostar shows promise for treating non-small cell lung cancer (NSCLC) patients who previously failed anti-PD-1 therapy.
- In a study with 23 participants, the overall response rate was 21.7%, and disease control rate reached 73.9%, with median progression-free survival of 4.3 months and overall survival of 9.8 months.
- Treatment-related adverse events occurred in over half of the patients (52.2%), with fatigue and hypothyroidism being the most common; however, no treatment-related deaths were reported.
Efficacy and Safety Analysis of Recombinant Human Endostatin (Endostar) Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer: A 2-Center Retrospective Study.
Technol Cancer Res Treat
July 2024
Department of Radiotherapy, ShuGuang Hospital, The Affiliated Hospital of Shanghai University of Chinese Traditional Medicine, Shanghai, China.
Background: This study aims to assess the efficacy and safety of Endostar in the management of locally advanced cervical cancer.
Methods: This retrospective, 2-center study enrolled 41 patients with locally advanced cervical cancer between June 2017 and December 2020. The patients were subjected to a combination of Endostar and chemoradiotherapy until they experienced disease progression or an unacceptable level of toxicity.
Effects of concurrent chemoradiotherapy with or without Endostar on the regression of retropharyngeal lymph node and prognosis of patients with locally advanced nasopharyngeal carcinoma: a retrospective study.
J Cancer Res Clin Oncol
May 2024
Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.
Background And Purpose: To investigate the effect of combining Endostar with concurrent chemoradiotherapy (ECCRT) compared to concurrent chemoradiotherapy (CCRT) on the regression rate of retropharyngeal lymph nodes (RLNs) and the relationship between regression rate of RLNs and prognosis of patients with locally advanced nasopharyngeal carcinoma (LANPC).
Methods: A total of 122 LANPC patients with RLNs metastasis were included. Metastatic RLNs were delineated both before and after treatment slice by slice on the magnetic resonance images cross-section.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!